Design and testing of hydrophobic core/hydrophilic shell nano/micro particles for drug-eluting stent coating by Du, Ruolin et al.
Du et al. NPG Asia Materials (2018) 10: 642-658
DOI 10.1038/s41427-018-0064-z NPG Asia Materials
ART ICLE Open Ac ce s s
Design and testing of hydrophobic core/
hydrophilic shell nano/micro particles for
drug-eluting stent coating
Ruolin Du1, Yazhou Wang1, Yuhua Huang1, Yinping Zhao1, Dechuan Zhang2, Dingyuan Du2, Yuan Zhang3,
Zhenggong Li3, Sean McGinty4, Giuseppe Pontrelli5, Tieying Yin1 and Guixue Wang1
Abstract
In this study, we designed a novel drug-eluting coating for vascular implants consisting of a core coating of the anti-
proliferative drug docetaxel (DTX) and a shell coating of the platelet glycoprotein IIb/IIIa receptor monoclonal
antibody SZ-21. The core/shell structure was sprayed onto the surface of 316L stainless steel stents using a coaxial
electrospray process with the aim of creating a coating that exhibited a differential release of the two drugs. The
prepared stents displayed a uniform coating consisting of nano/micro particles. In vitro drug release experiments were
performed, and we demonstrated that a biphasic mathematical model was capable of capturing the data, indicating
that the release of the two drugs conformed to a diffusion-controlled release system. We demonstrated that our
coating was capable of inhibiting the adhesion and activation of platelets, as well as the proliferation and migration of
smooth muscle cells (SMCs), indicating its good biocompatibility and anti-proliferation qualities. In an in vivo porcine
coronary artery model, the SZ-21/DTX drug-loaded hydrophobic core/hydrophilic shell particle coating stents were
observed to promote re-endothelialization and inhibit neointimal hyperplasia. This core/shell particle-coated stent
may serve as part of a new strategy for the differential release of different functional drugs to sequentially target
thrombosis and in-stent restenosis during the vascular repair process and ensure rapid re-endothelialization in the field
of cardiovascular disease.
Introduction
Cardiovascular diseases are among the most common
diseases that give rise to disability and mortality. Cur-
rently, the use of coronary stents is commonplace in the
treatment of such diseases1. Extensive data from experi-
mental and clinical studies confirm that although drug-
eluting stents (DESs) reduce the rate of restenosis com-
pared with bare-metal stents (BMSs), there remains an
increased risk of late stent thrombosis with DESs2–6.
Percutaneous coronary intervention (PCI), especially
involving stents, usually results in injury to the endothe-
lium, consequently inducing the activation and gathering
of blood platelets to form thrombosis, and the stent may
become a site for the adhesion of platelets before they
are completely covered by neointima4,7. Other long-term
clinical studies have reported that DESs loaded with anti-
proliferative agents suppressed the growth of neointima,
delayed the re-endothelialization of stents, lengthened the
time for activation of platelets, and increased the risk of
late thrombosis8. Hence, the design of DESs in the future
must consider these critical issues.
The anti-proliferative drugs rapamycin (also known as
sirolimus) and paclitaxel were the first-generation drugs
coated with DES approved by the US FDA. Subsequently,
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as newer-generation stents have emerged, sirolimus analo-
gues such as zotarolimus and everolimus have been utilized.
Despite these advancements, today’s DES have not com-
pletely eradicated restenosis and still lead to a higher
incidence of late stent thrombosis. Drug docetaxel (DTX)
is a paclitaxel analogue with enhanced anti-proliferative
ability and water solubility and has been shown to be a
good candidate drug for the prevention of restenosis9,10.
Thrombosis remains a concern after stent implantation,
whether at the early or very late stage. The exposure of
damaged endothelial cells to the blood activates platelet
adhesion and aggregation. The binding of the monoclonal
antibody (mAb) to the platelet GP IIb/IIIa receptor11 has
potent anti-platelet and anti-thrombotic characteristics
that have been shown to reduce thrombosis-related major
complications after coronary angioplasty12–14.
Polymer particles can be employed to deliver medica-
tion in a rate-controlled and sometimes targeted manner
by drug leaching from the polymer or by degradation of
the polymer matrix15. The advancement and convergence
of particle drug delivery systems have recently been
explored to optimize stent coatings. For example, drugs
exhibiting different therapeutic effects were encapsulated
in bi-layered PLGA particles containing vascular endo-
thelial growth factor (VEGF) plasmid and paclitaxel;
stents with this particle coating promoted early endo-
thelium healing and inhibited smooth muscle cell (SMC)
proliferation16–18. Local particle-based drug delivery was
hypothesized to facilitate high regional concentrations
of therapeutic agents with prolonged retention at low
doses, leading to reduced systemic toxicity19,20. For drug
loading and release of particles, there already exist several
approaches21. Traditional particle preparation methods
cannot adequately control the burst release of drugs22.
Electrospraying, on the other hand, provides a superior
alternative to producing stent coatings with different
nano/micro particle sizes and assembly methods. Thian
et al.23 used electrospraying deposition to produce a
uniform coating consisting of hydroxyapatite nanocrystals
on a titanium substrate, which triggered an early apatite
precipitation process in cellular-simulated body fluid.
Almería et al.24 demonstrated a multiplexed electro-
spraying process for the single-step synthesis of stabilized
polymer particles for drug delivery, but the release rate of
the drugs was found to be rapid, reaching approximately
70% within the first 4 h. To the best of our knowledge,
only a limited number of studies have reported the
application of electrospraying for the fabrication of vas-
cular DES coatings. In particular, Dong et al. fabricated
and controlled the release of the electrosprayed ReoPro-
loaded metal vascular stent. Hydrophilic ReoPro release
was controlled in the hydrophobic PLGA-based release
system and was effective in suppressing platelet adhesion
and SMC overgrowth for vascular stents25. Zamani’s
research showed that multi-drug coatings could easily
be fabricated using electrospraying. The electrosprayed
Montelukast/poly(lactic-co-glycolic acid) particle-based
coating is a potential new therapeutic approach toward
the prevention of in-stent restenosis26.
Ideal vascular implant coatings should exhibit a number
of properties. These properties include biocompatibility,
anti-thrombogenicity, the ability to interface with anti-
proliferative drugs to reduce platelet activation level and
time, restenosis prevention and a favorable surface topo-
graphy for re-endothelialization27,28. To achieve dual-
functionalized vascular stents with dual drugs, researchers
have chosen to combine various coating methods and
multiple-step methods for coating preparation29,30. To the
best of our knowledge, there is no published work that
considers multi-hydrophilic/hydrophobic drug coating
preparation for coronary stents with a single step. In our
previous research, we reported the detection of sequential
drug release of polymer-controlled core/shell nanoparticles
prepared by coaxial electrospraying31. Here, we designed
a novel DES coating consisting of particles with a core
of the anti-proliferative drug DTX and a shell of SZ-21,
which was the platelet glycoprotein IIb/IIIa receptor
monoclonal antibody32,33. The particles were produced and
deposited on the stent by coaxial electrospraying (Fig. 1).
Materials and methods
Materials
Three hundred sixteen liters (316L) stainless steel (SS)
stents (3.0 × 17mm) and 316 L SS sheets (Ø 10 × 1.5mm)
were purchased from Beijing AmsinoMed Medical Device
Co., Ltd., China. SZ-21 was supplied by Prof. Changgeng
Ruan in the Jiangsu Institute of Hematology (First Affiliated
Hospital of Suzhou University, Suzhou, China). Human
umbilical vein endothelial cells (HUVECs) and Human
umbilical arterial smooth muscle cells (HUASMCs) were
a generous gift from Dr. Lushan Liu (Nan Hua University,
China). DTX (Xieli Pharmaceutical Co., Ltd, Sichuan,
China), chitosan (CS) Mw= 600,000 (Boxin Biotech Co.,
Ltd, Tianjin, China) and poly [(50% lactic acid) (50% glycolic
acid)] (PLGA) Mw= 20,000 (Sigma Inc., St. Louis, USA)
were also used in these studies.
Multilayer coating with hydrophobic core/hydrophilic shell
nano/micro particles by electrospraying
Coating experiments were carried out on 316 L SS
stents (3.0 × 17 mm) and 316 L SS sheets (Ø 10 × 1.5 mm)
utilizing coaxial electrospraying. The design and experi-
mental setup of the coating procedure are shown in Fig. 1.
Dichloromethane and ethylic acid solution were used
as the solvents for PLGA and CS, respectively. In the
electrospray coating process, 10mL syringes containing
DTX-PLGA solution (DTX concentration at 1mg/mL) or
SZ-21-CS solution (SZ-21 concentration at 2mg/mL) were
Du et al. NPG Asia Materials (2018) 10: 642-658 643
connected with a coaxial nozzle. The reception distance
between the tip of the needle to the coating surface was
maintained at 5–15 cm; the voltage and inner/outer flow
rate were changed to obtain a uniform coating (Table S1).
The SZ-21/DTX drug-loaded hydrophobic core/hydrophilic
shell particle coating (DPC) and no drug core/shell particle
coating (BPC) were prepared according to the following
selected parameters: 0.2mL/h (inner) and 0.6mL/h (outer),
a PLGA concentration of 10mg/mL, a CS concentration
of 2.5mg/mL, a reception distance of 5 cm, and a voltage
of 14 kV. The morphology, core/shell structure, and
particle size distribution were detected through a fluores-
cence microscope (IX81, Olympus, Japan), scanning
electron microscope (SEM; Vega-LMH, Tescan, Czech),
confocal microscope (SP8, Leica, German) and transmission
electron microscope (TEM, JEM-2100F, JEOL, Japan).
Morphometric analysis of the SZ-21/DTX drug-loaded
hydrophobic core/hydrophilic shell particle coating stent
(DPS)
Fluorescence characterization of DPS
DPS was prepared by coaxial electrospraying. To iden-
tify the hydrophobic core/hydrophilic shell particle nature
of the coating, 1 mg/mL fluorescein isothiocyanate (FITC)
was added to the shell solution and 1mg/mL rhodamine B
was added to the core solution, allowing for observation
by fluorescence microscope (IX81, Olympus, Japan).
SEM and EDS test of DPS
After coating, DPS was expanded three times for 30 s
each time by balloon (2.75 mm× 18mm MAVERJCK2,
Boston scientific) at 10 atm in vitro; the changes in
morphology and element contents of BMS, DPS and
after expansion were all determined using a scanning
electron microscope (SEM; Vega-LMH, Tescan, Czech)
and energy dispersive spectrometer (EDS; INCA x-sight
7557, Oxford Instruments, UK), respectively.
Atomic force microscopy and water contact angle analysis of
DPS
The morphology changes of stents with different coat-
ings were characterized using an atomic force microscope
(AFM; SPI3800N, SEIKO, Japan). The hydrophilicity
alteration of different coating surfaces, as determined by
the distilled water contact angle, was measured with a
contact angle tester (DSA30, Krüss, Germany) at room
Fig. 1 Schematic diagrams of material design and function hypothesis. The PLGA solution with DTX and chitosan solution with SZ-21 were
affused in two syringes separately and placedon the coaxial electrospraying device. Injecting the solutions at a constant rate, the coaxial nozzle was
given high voltage, and the dissolvents of the two solutions were volatilized to form dual core/shell drug particles. The dual drug particles were
deposited on the surface of the stent to form the DPS. The differential release of SZ-21/DTX was assumed, and the mechanism of their function was
shown. The differential releasing pattern allows rapid re-endothelialization in the early days and the later inhibition of smooth muscle cell
proliferation
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temperature. Three different sites were selected randomly
for each group.
Fourier transform infrared spectroscopy (FTIR) detection of
drugs and polymers for DPS
FTIR measurement was performed to analyze the che-
mical structure of the coaxial sprayed coatings before and
after coaxial electrospraying. Using the squash method,
KBr (100–200mg) and solid samples (1–2mg) were
ground into micron powder and pressed into sheets
(Ø 13 × 1.0 mm) for analysis.
Drug release analysis in vitro
Detection of drug release in vitro
For drug release analysis, DPSs were transferred in 1mL
phosphate-buffered saline (PBS) in a constant tempera-
ture shaking incubator at 60 rpm/min and 37 °C.
The concentrations of released drugs were monitored at
pre-determined time points, and the fresh PBS was
replaced each time. Moreover, the stent morphology
after 0, 7, and 28 days was characterized by SEM. The
SZ-21 release rate in vitro was tested using mice immu-
noglobulin IgG Elisa kits. DTX was assayed by HPLC
(Agilent 1100, USA) with a C18 250 mm× 4.6 mm
column. The mobile phase was acetonitrile: water (65:35).
The sample was eluted at 1 mL/min at room temperature,
and the absorbance was measured at 230 nm.
Mathematical modeling of drug release in vitro
The large number of core/shell particles on the
coating made it impractical to mathematically model each
individual particle. Instead, we adopted a continuum
approach and approximated the core/shell coating layer as
a biphasic material, providing two independent routes of
transport for each drug. These two routes could result
from surface preparation methods and may correspond to
the drug phases being either fully embedded within the
coating layer (slow release) or connected to the surface by
pores or other defects (fast release)34.
Each route of transport was associated with a different
effective transport speed characterized by a rate constant
ki, i= 1,2. Assuming that the drug was initially uniformly
distributed within each respective route, the strut was
impermeable to drug transport, the release medium acted
as an infinite sink and the drugs were dilute, and then
considering drug transport within each route as a
diffusion-dominated process, we derived an expression for
the mass of each drug within the coating as a function of
time, M(t):
M tð Þ ¼
X1
n¼1
A nð Þ r eK1 nð Þt þ 1 rð ÞeK 2 nð Þt
n o
ð1Þ
where
A nð Þ ¼ 8M0
π2 2n1ð Þ2 ;K1 nð Þ ¼
2n1ð Þ2π2k1
4 ;K2 nð Þ ¼ 2n1ð Þ
2π2k2
4 ,
and r is the initial fraction of the total drug loading (M0)
within each route.
Using the knowledge of the total drug loading for each
drug and Eq. (1), we calculated the cumulative fraction of
each drug that had been released as a function of time.
Blood compatibility evaluation
Blood was obtained from healthy volunteers in accor-
dance with the protocol approved by the Blood Donation
Law of the People’s Republic of China. To isolate fresh
human platelet-rich plasma (PRP), the blood was cen-
trifuged at 1200 rpm for 10min, and the supernatant
was collected. All sheets were incubated in 0.5 mL of PRP
for 30min at 37 °C, rinsed with PBS, fixed with 2.5%
glutaraldehyde for 12 h at 4 °C and dehydrated for SEM35.
The expression of platelet granule membrane glycopro-
tein CD62P was detected to evaluate the anti-platelet
activation of the coating. The deformability of adherent
platelets (type I-V) on coatings was analyzed, and the
morphological indices were calculated via the following
formula:36
morphological index
¼ No:type I ´ 1þ No:typeII ´ 2þNo:type III ´ 3þ No:type IV ´ 4þ No:typeV ´ 5ð Þ
total number of adherent platelets
ð2Þ
The hemolysis ratio of DPC was tested following the
Chinese national standard (Biological Evaluation of
Medical Devices—Part 4: Selection of Tests for Interac-
tions with Blood, GB/T 16886.4-2003). The activated
partial thrombin time (APTT) and prothrombin time (PT)
were applied to evaluate the anti-thrombogenicity of
stents in vitro37.
The proliferation and migration of HUVEC and HUASMC on
coatings
Cell culture
HUVECs and HUASMCs were cultured in RPMI 1640
and DMEM/F12 media (HyClone, USA), respectively,
supplemented with 10% fetal bovine serum (FBS; Cam-
brex Corp, USA) and 1% P/S (Gibco Industries Inc, USA)
at 37 °C under 5% CO2.
HUVECs seeding and cell viability assay
A rotation culture device after autoclave sterilization
was used to seed cells on the stent surface. BMS, BPS, and
DPS were transferred to the rotation culture tubes after
undergoing ultraviolet irradiation sterilization. Then,
HUVECs were seeded in the tubes at 5 × 104 cells/tube
density with 10 rpm/min for 12 h at 37 °C. Finally, the
stents were gently taken out in an aseptic condition and
cultured in 12-well plates at 37 °C under 5% CO2
38.
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After a 5-day culture, the stents were immobilized with
2.5% glutaraldehyde and dehydrated for morphological
observation by SEM. The proliferation rates of cells on
the stent surfaces were investigated with Cell Titer 96®
Aqueous One Solution Cell Proliferation Assay after 1, 3,
and 5 days. The relative growth of rate (RGR) was cal-
culated by this formula:
RGR ¼ ODt
ODnc
 
´ 100% ð3Þ
(where ODt represents the experimental group, and
ODnc represents the negative control group).
After co-culturing for 1, 3, and 5 days, the culture
supernatant was collected by centrifuging at 3000 rpm for
10min. The nitric oxide (NO) release levels and total
antioxidant capacity (T-AOC) of HUVECs were tested.
The migration of HUVECs and HUASMCs on coatings
HUVECs and HUASMCs were cultured separately.
Both HUVEC and HUASMC migration assays were car-
ried out with the classical scarification method. Different
coatings were sprayed on 316 L SS sheets by coaxial
electrospraying. Then, the sheets of three groups (316 L
SS, BPC, DPC) were placed in 24-well plates after
undergoing ultraviolet irradiation sterilization for 12 h.
One milliliter of cell suspension (1 × 105 cells/ml) was
seeded and grown on the coating surfaces. After being
starved in media with 1% serum for 4 h, confluent
monolayers of HUVECs were wounded by scraping a
pipet tip (200 μL) across the monolayer to produce initial
wounds with a constant diameter; they were then washed
three times with PBS. The migration distance of the
scratch was measured at 0, 6, 12, and 24 h using ImageJ
(NIH, US). The migration lengths were counted following
the methods in our previous research38.
Stent implantation in vivo
Two groups of drug-coated stents were prepared using
coaxial electrospraying: DPSs containing 50 ± 2.36 μg
DTX (DPS-L) and DPSs containing 100 ± 3.88 μg DTX
(DPS-H). The DTX content on the two stent groups was
detected in the drug release after complete elution. Three
control groups, BMS, BPS, and SES (DES with Sirolimus),
were also prepared.
Twenty male Bama minipigs (30–40 kg) fed a normal
diet were used in this study in accordance with the
guidelines of the Chinese Animal Care and Use Com-
mittee standards. Three days before surgery, 150mg
aspirin and 300 mg clopidogrel were administered orally
with feed. Before surgery, an intramuscular injection of
xylazine hydrochloride (0.15 mL/kg, 30 mg/1.5 mL) was
given to each minipig for muscle relaxation. The venous
channel was set up at the edge of the ear vein, and blood
was taken simultaneously for a routine blood examination
and serum biochemical examination, followed by ear
intravenous administration of propofol at 8 ml/h for
anesthesia. Minipigs were fixed to the operating table in a
lateral position, and a 6F introducer sheath was positioned
in the right femoral artery under surgical exposure.
Heparin sodium (200 IU/kg) was injected via the sheath.
All catheters were subsequently introduced through the
sheath and advanced to the left anterior descending
(LAD)/left circumflex (LCX)/right coronary artery (RCA)
through a guide wire. Baseline angiograms of each artery
were obtained for each pig through quantitative coronary
analysis (QCA). Prepared stents were deployed in the
suitable vessel region during angiographic guidance.
It was ensured that no branches were present in the
stented region. Stents were dilated at 10 atm. At the level
of the balloon dilatation, the diameter of the aorta was
approximately 2.5 mm and the expansion ratio of the
aorta was 1:1.1. Two different stents were deployed per
pig, and pre-deployment and post-deployment digital
subtraction angiography was recorded. Gentamicin sulfate
(5 mg/kg) was given as intramuscular injection in the next
three days, and 150mg aspirin and 300 mg clopidogrel
were administered orally with feed every day. Animals
were fed a normal diet after the intervention.
Acquisition and observation of stent implantation samples
Pigs were euthanized at 1, 3, and 6 months (n= 3 at
each time point for each stent group). At each time point,
aortic specimens were excised transversely into two
parts. One part was fixed in 4% paraformaldehyde and
embedded in light-cured resin with hematoxylin and
eosin stain (HE) for pathology organization analysis.
Another part was fixed in 0.25% glutaraldehyde for 48 h,
and the morphology of the intima surface was observed
by SEM. The proximal part and distal part of each stented
vessel, myocardium, liver, spleen, lung, and kidney of
pigs were fixed and sliced to check the safety of stents.
Histomorphometric analysis was conducted on each
section, including the vessel area (mm2), internal elastic
lamina (IEL) area (mm2), lumen area (mm2), neointima
area (mm2), and the neointima thickness (mm) by Image
Tool. The percentage of restenosis was calculated using
the following equation:
Restenosis rate %ð Þ ¼ 1 lumen area
internal elastic lamina area
´ 100%
ð4Þ
Venous blood of pigs was collected for routine blood
examination and serum biochemical examination.
Statistical analysis
At least three independent experiments were performed
for the tests described above. Statistical analyses were
conducted with GraphPad Prism 6. The differences
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between experimental groups were considered statistically
significant when p < 0.05. Unless indicated, the values
are expressed as the mean ± SD.
Results
Optimization of electrospraying parameters and
preparation of dual-drug-loaded particles
It was recognized that different parameters of the
electrospraying process have a direct impact on the
morphology of the particles. Because of the different
viscosities of CS and PLGA, the formation of the Taylor
cone at the coaxial nozzle was observed and recorded
during spraying. The electrospraying parameters are
shown in Table S1. Our results showed that micro-
particles were well separated at flow rates of 0.2 mL/h
(inner) and 0.6 mL/h (outer), with a PLGA concentration
of 10 mg/mL, a CS concentration of 2.5 mg/mL, a
reception distance of 5 cm and a voltage of 14 kV
(Table S1) (Fig. 2a). The morphology of the hydrophobic
core/hydrophilic shell particles was observed by SEM
(Fig. 2b, c). The core/shell structure was viewed via con-
focal microscopy and TEM (Fig. 2d-g). The particles were
found to be well-dispersed, with most assuming uniform
spheres with diameters of 643 ± 34 nm and 1067 ± 53 nm
(Fig. 2h). The prepared particles dispersed evenly on the
receiving surface with no large aggregation effect.
Surface morphology of DPS
The DPS had both green fluorescence (shell) and red
fluorescence (core) distributed uniformly on the surface
(Fig. 3a). The 316 L SS stent surface was smooth and
clean after pretreatment, and the surface was very uni-
form with no coating aggregation after coating (shown
in Fig. 3b). Furthermore, after expansion, each coating
was still homogeneous, smooth, and intact without
cracking, tilting or shedding.
The change of surface morphology after each coating
was investigated by AFM. After an acid pickling pre-
treatment, the 316 L SS stent surface was extremely
uneven, with a surface roughness of Ra= 30.6 ± 0.26 nm.
However, the surface roughness significantly increased to
Ra= 43.2 ± 0.42 nm after coating (Fig. 3c). Because the
coating consisted of hydrophobic core/hydrophilic
shell nano/micro particles, the surface became undulating
and the contact angle of the 316 L SS surface increased
from 39.65 ± 2.19° to 69.07 ± 2.89°(Fig. 3d).
Here, we mainly used FTIR to detect any functional
group change of drugs and polymers before and after
spraying that may have resulted from the high voltage and
solvent changing the drug structure and inducing a che-
mical reaction between the drug and polymer. The main
functional group of each of the drugs and polymers were
clear: –OH/–NH of SZ-21 at 3410 cm−1, –OH/–NH
superimposed absorption peak of chitosan at 3410 cm−1
and CH2 at 2925 cm
−1and 1467 cm−1 and C–O at 1000
cm−1; additionally, several absorption peaks of DTX
and PLGA were shown at 3400–3500 cm−1. SZ-21 and
DTX mainly existed with polymers due to physical
adsorption (Fig. 3e).
Drug release from DPSs in vitro
We tested the drug release characteristics of DPSs
via a constant temperature horizontal rocking bed.
Within the first 12 h, the SZ-21 (shell) release was
26.70 ± 0.61% of its initial loading, while the DTX (core)
release was only 5.80 ± 0.36% of its initial loading
(Fig. 4a). The release of the shell drug dose rapidly
reached a ratio of three times that from the core. By
7 day, the SZ-21 release had reached 37.9 ± 0.74%,
while DTX release was still markedly slower at 17.70 ±
0.73% (Fig. 4a). The release of two drugs was relatively
stable for the next few days. After 28 days, the cumulative
release of SZ-21 reached 62.30 ± 0.58%, and that of
DTX reached 38.41 ± 0.66%. Throughout the 28 days,
the cumulative release of SZ-21 was always higher than
that of DTX.
To evaluate the drug release pattern of the coating,
we carried out an analogue analysis. With the M0 mea-
sured from our experiments, we conducted a standard
least squares analysis, utilizing the analytical solution
(1) in conjunction with the experimental data (Fig. 4b)
to inversely estimate the unknown parameters r, k1
and k2 for which the model solution best fit the
data for each drug. We observed that the release of
each drug was well-described by this simple biphasic
release model.
The surface topographies of DPSs were investigated by
SEM after 0, 7, and 28 days (Fig. 4c). The stents presented
a relatively smooth morphology prior to release (0 day).
After 7 days, the morphology and glossiness of the stents
showed no obvious differences with those from before,
and the coating also had no obvious degradation. How-
ever, a shedding phenomenon appeared around the
areas of light curvature (7 days). However, after 28 days,
the surface of the coating displayed more particles, and
the stent became uneven (yellow arrow and curve)
because of the degradation of the coating (28 days).
Blood compatibility of the DPC
In general, platelet morphologies are related to their
degree of activation. The number and morphology of
platelets on the surface of DPC sheets were compared
with 316 L SS and BPC (Fig. 5a, b). The DPC surface
showed the least number of adherent platelets with a
round shape and few pseudopodia. The DPC significantly
decreased platelet activation, as seen through the
expression of the platelet membrane glycoprotein CD62P
(Fig. 5d). Further analysis of platelet type showed that
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most of the adherent platelets on the 316 L SS, BPC,
and DPC surfaces were types I–III (Fig. 5c), and the
morphological indices of DPC (2.83 ± 0.26) were lower
than those of 316 L SS (2.93 ± 0.18) and BPC (2.91 ± 0.21),
which indicated less platelet activation on DPC. In addi-
tion, the hemolysis ratios of all samples were well within
1% (Fig. 5e), which suggested that DPC had excellent
hemocompatibility. The APTT (89.33 ± 2.52 s) of DPC
were significantly prolonged compared with those of 316
L SS (38.02 ± 3.12 s) and BPC (52.33 ± 3.05 s). The PT of
the three groups showed a similar trend of 26.67 ± 1.61 s
for DPC, 14.33 ± 1.53 s for 316 L SS and 18.33 ± 2.31 s for
BPC (Fig. 5f, g).
The proliferation and migration of HUVECs and HUASMCs
on DPC
The structure of the hydrophobic core/hydrophilic
shell particles ensured that the anti-proliferative drug in
the core released very slowly, having little influence on
HUVEC adhesion and proliferation. In fact, the coating
showed a promotion of HUVEC proliferation in the
early days (Fig. 6a), while the low dose of DTX sig-
nificantly inhibited the proliferation of HUVSMCs
(Fig. 6b). Figure S1 (A-F) showed an SEM image of
HUVEC adhesion on the BMSs, BPSs, and DPSs. After
5 days, cells were spindle-shaped or irregular triangle-
shaped on the surface of the three groups, and the
number of cells had no significant difference. The NO
release and T-AOC of HUVECs were not influenced by
the release of DTX (Figure S1G, H).
The migration ability of HUVECs and HUASMCs on
316 L SS, BPC, and DPC were tested in a scratch wound
model in vitro. Due to the release of DTX, the migration
distances of HUVECs in the DPC and BPC groups were
less than those of the control group (Fig. 6c, e). The
inhibition of HUASMC growth in the DPC group was
obvious, the intercellular space was increased and the
number of cells was less than those in the other two
Fig. 2 The morphology and sizes of the SZ-21/DTX drug-loaded core/shell particles. The morphology of particles under the optical microscope
(a) and SEM (b, c). d–g The core/shell structure was shown with confocal microscopy (d–f) and TEM (g).These particles were well separated and
mostly spherical. The maximum diameter of these particles was nearly 1 μm (h)
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groups. During the 24-h migration, the migration length
of HUASMCs in the DPC group was inhibited and
notably delayed compared with the other two groups
(Fig. 6d, f).
In vivo stent implantation and animal survival after
surgery
In total, 36 stents (number of stents in each group >5)
were implanted successfully into 20 Bama minipigs
(Figure S2). Subsequently, the animals were revived and
returned to the breeding center for normal feeding.
During the feeding period, all physiological indices of
porcine health, such as diet and weight, were normal.
There were at least two different stents implanted in
the coronary of each minipig; the main indicators of
routine blood examination and serum chemical exam-
ination exhibited no significant changes after stent
implantation for 12 months. The color, luster, and hard-
ness of heart, liver, spleen, lung, and kidney were normal,
and the HE stain indicated no obvious organic issues.
These data showed that all stents were safe and had no
significant toxicity (Table S2, S3, Figure S3).
Coronary angiography
Coronary angiography was performed after stent
implantation immediately and at 1, 3, and 6 months. After
stent implantation for 1, 3, and 6 months, angiography
showed that all of the vascular walls were smooth, with no
obverse in-stent thrombosis, and there were no signs of
stent malapposition in any of the groups (stent is shown
with blue arrow) (Fig. 7a). The rate of lumen loss after
1 month showed no significant difference among all
groups (p < 0.05) (Fig. 7b). After 3 months, the BPSs
showed a significant difference from the DPS-H group
Fig. 3 Evaluation of the surfaces of different stent coatings. a Core (red)/shell (green) drug-loaded particles were prepared on the surface of
stents by coaxial electrospraying. b The surface of BMSs was smooth and uniform, while the DPS surface was roughened and exhibited no loss, tilt
and cracking in the binding parts of different stents after the expansion. The carbon and oxygen weight percentages of DPS before and after
expansion are shown in the image. c The roughness of DPSs (right) increased compared to that of the 316 L SS (left) observed by atomic force
microscopy. d The contact angle of DPSs significantly increased but was still less than 90°, which means that it remained hydrophilic. e FTIR of drug
coating for the DTX, SZ-21, chitosan PLGA, and particle coating. The main functional group of each of the drugs and polymers existed; SZ-21 and DTX
mainly existed with polymers in the form of physical adsorption
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(p < 0.05) (Fig. 7c). The rate of lumen loss after 6 months
showed that the BPS and SES groups exhibited a
significant difference compared with the DPS-H group
(p < 0.05) (Fig. 7d).
DPS promoted re-endothelialization in vivo
After implantation for 1, 3, 6, and 12 months, the pro-
gress of re-endothelialization was examined by SEM. The
progress of re -endothelialization of coronary in all groups
was almost completed within 1 month, and the surfaces of
all stent groups were covered partially with cobblestone-
like endothelial cells. After 3 and 6 months, the DPSs-H
had adhered to them a small amount of platelet and fibrin,
and the morphology of the adhered cells became oval
following the initial roundness. The BPSs and SESs
seemed to have clearer stent shapes (Fig. 8 and Figure S4).
These data suggested that the antiplatelet aggregation and
re-endothelialization were enhanced in animals treated
with DPS and not adversely affected by the loaded
DTX. After implantation for 12 months, the surfaces of
the BMS, BPS, and DPS-H groups were more or less
covered with some platelet and fibrin, while the surface
on the BMS group had the maximum amount of platelet
and fibrin. Most cells on the surface of the BMS were
spindle-shaped, which was different from the other
groups (Figure S5).
Reduced in-stent restenosis in porcine coronary arteries
after DPS implantation
To evaluate the effects of DTX eluted from stents
in vivo, a histomorphometric analysis was performed in
the BMS, BPS, SES, and DPS group after implantation for
Fig. 4 In vitro Drug release of DPS. a Within 12 h, SZ-21started to release and reached 26.70 ± 0.61%, while only 5.80 ± 0.36% of DTX was released.
After 28 days, the cumulative release rate of SZ-21 reached 62.30 ± 0.58%, and that of DTX was 38.41 ± 0.66%. b Comparison of in vitro release
between mathematical model and experimental data. The best-fitting parameters were found to be r= 0.118 day−1, k1= 0.330 day
−1 and k2=
0.00642 day−1 for DTX and r ¼ 0:258; k1 ¼ 6:31day1 and k2 ¼ 0:0358 day1 for SZ-21. c The stents presented a relatively smooth morphology at
0 day. After 7 days, the coating had no obvious degradation, but a shedding phenomenon appeared around the corners. After 28 days, the coating
became rugged, and the loss of coating could be clearly observed (areas marked by a yellow line and arrow)
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1 and 3 months (Fig. 9a). Endothelial repair was com-
pleted in all groups, and the stent surface was covered
with intact intima. Compared to that of BMS and BPS, the
elution of DTX from DPS-Hs significantly reduced the
mean neointimal area and the percentage luminal stenosis
and showed a similar anti-restenosis effect (Fig. 9b, c).
Above all, the DPS-Hs had a better anti-restenosis effect,
while the BPSs produced the poorest results. After
implantation for 6 months, there was no thrombosis or
obvious intimal hyperplasia in the groups. No statistically
significant difference was observed between the BMS
and DPS groups (Figure S6).
Discussion
The introduction of DESs led to a significant reduction
in restenosis and demonstrated early improvements in
safety after PCI39. However, their use is associated with
an increased risk of late ST and considerable restenosis
rates40; these remaining issues have driven the design of
new stent technology41. In the present report, we descri-
bed a novel DES coating consisting of particles with a core
of the anti-proliferative drug DTX and a shell of SZ-21
deposited by coaxial electrospraying, which provides
the biphasic diffusion-controlled release of each drug
to effectively reduce in-stent restenosis and thrombosis.
Fig. 5 The blood compatibility of DPC. a Only a small number of platelets adhered to the DPC surface and were not activated, which was
significantly lower than those of 316 L SS and BPC. b The quantitative analysis of platelets that adhered. c The percentage of type III platelets were the
highest in each group; the platelet activation on the DPC surface was much lower than other two groups, while the polymer coating showed the
highest platelet activation. d The platelet α-granule membrane protein levels of different coatings. e The hemolysis ratios of all samples were well
within 1%. f, g The APTT and PT of DPC surface were significantly higher than those of 316 L SS and BPC (*, significant difference p < 0.05; **,
significant difference p < 0.01)
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After PCI, the injured vessel undergoes a variable
combination of platelet activation and acute thrombosis,
intimal proliferation, vascular remodeling/wound
contraction, and recoil of the normal section of the
artery42. For the second generation of DESs, whose
coatings mostly delivered paclitaxel and sirolimus
Fig. 6 The proliferation and migration of HUVECs and HUASMCs on 316 L SS, BPC, and DPC. a, b The coating showed a promotion of HUVEC
proliferation and the inhibition of HUASMC proliferation in the early days. c, e The migration distance of HUVECs. The white line is the primary wound
of the cell layer, the red line is the front of cell migration; the migration distance of HUVECs in the DPC group only showed significance at 24 h
compared with 316 L SS and BPC. d, f The migration distance of HUASMCs. The migration distance of HUASMC in DPC group was obviously shorter
compared with those of 316 L SS and BPC (*, significant difference p < 0.05; **, significant difference p < 0.01)
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together with their analogues43, the coating could only
achieve short-term anti-proliferative function with
delayed re-endothelialization. Most vascular stent coat-
ings that have been produced have been given only one
kind of function, such as the inhibition of inflamma-
tion44,45, promotion of re-endothelialization46 or a novel
way of preventing in-stent restenosis47. In our design,
we arranged the coating to have dual anti-thrombosis
and anti-restenosis functions. The efficient platelet GP
IIb/IIIa receptor monoclonal antibody SZ-2136 and anti-
proliferative paclitaxel analogues DTX48,49 were chosen
for anti-thrombosis and anti-restenosis, respectively. To
prepare core/shell structure particles for both hydrophilic
and hydrophobic drugs, we chose CS as the carrier of SZ-
21 to be the shell and PLGA as the carrier of DTX to be
the core. The CS is an appropriate carrier for protein and
other activated materials50,51, and PLGA is an FDA-
approved carrier.
The most popular preparation methods for stent coat-
ing include dipping52 and spraying53,54, but such methods
are unwieldy considering the hydrophobicity and hydro-
philicity of the drugs. Hossfeld et al.55 prepared a bioactive
coronary stent coating based on layer-by-layer technology
for siRNA release, whereas Song et al.56 demonstrated
multi-step immersion for the simultaneous coating of
VEGF and anti-CD34 antibody. In this study, we sought to
fabricate a novel hydrophobic core/hydrophilic shell
particle coating on the surface of the implant using
coaxial electrospraying. Moreover, the core/shell is
interchangeable according to the research purpose and
Fig. 7 Coronary angiography of stent implantation in vivo. a After stent implantation for 1, 3, and 6 months, all of the vascular wall was smooth,
with no obverse in-stent thrombosis, and there are no signs of stent malapposition in any of the groups (stents are shown with blue arrows). b The
rate of lumen loss after 1 month was not significant among all groups. c After 3 months, the BPS showed a significant difference compared with
the DPS-H group. d After 6 months, the BPS and SES groups showed a significant difference compared with the DPS-H group (*, significant difference
p < 0.05)
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the design of experiments by altering the parameters of
coaxial electrospraying57. We focused on the type and
concentration of polymer, voltage, flow rate, and recep-
tion distance; these factors control the coating and ensure
precision as well as reproducibility58. The voltage affected
the formation and stabilization of the Taylor cone. The
feeding speed of the sample influenced the formation and
size of the particles, directly affecting the quality of the
coating. Particles obtained via electrospraying were well
separated and most spherical.
The surface of the stent contacts the blood and vascular
tissue synchronously, and it is known that the coating
influences the long-term outcomes of stent implanta-
tion59. We observed the distribution of green fluorescence
and red fluorescence on the stent. The results demon-
strated that the coating was excellent, with a uniform
surface. Changes in surface hydrophilicity may cause
quantitative and qualitative variations in absorbed pro-
teins, which can directly influence the biocompatibility of
the materials60. To evaluate the changes in hydrophilicity
of the surface after each coating, the water contact angles
on material surfaces were measured. After coating, while
CS was a hydrophilic material and contributed to the
shell particles, the contact angles of the coating were less
than 90°; the coating therefore retained its hydrophilicity.
The aggregation and activation of adherent platelets
are considered key indicators for evaluating the hemo-
compatibility of a material. Our results indicated that
the SZ-21 on DPSs could inhibit platelet adhesion and
aggregation and prolong APTT, PT, and TT values, which
suggested that SZ-21 may contribute to inhibiting the
thrombosis of the stent section after DPS implantation.
Nano/micro particles have previously been used to
achieve multi-drug delivery from drug delivery systems61.
In this study, we loaded two drugs with hydrophilic dif-
ferences via coaxial electrospraying. The solvent of PLGA
and DTX in the core of particles was dichloromethane;
the solvent of CS and drug SZ-21 in the shell was acetic
acid. The release profiles of the drugs were found to
be markedly different, with SZ-21 being released faster,
followed by DTX. The hydrophobic core/hydrophilic
shell particles controlled the release of two drugs to
realize a differential release, which may well hold advan-
tages for adequate vessel repair over a single drug.
We have shown that the in vitro DPS was a diffusion-
controlled release system well-described by a biphasic
mathematical model. Moreover, we have inversely esti-
mated the parameters associated with the model. The
model suggested that for both drugs, the majority of the
drug was released initially within the slow-release phase
(88.2% for DTX and 74.2% for SZ-21). In the case of
DTX, the fast phase release rate was more than 50 times
greater than the slow release rate (k1= 0.330 day
−1, k2=
0.00642 day−1) while for SZ-21, the corresponding ratio
was more than 176 (k1= 6.31 day
−1, k2= 0.0358 day
−1).
Comparing the two drugs, the fast phase release rate of
SZ-21 was more than 19 times greater than that of DTX,
while the slow release rate was over five-fold greater
for SZ-21. While such modeling allows for the time-
dependent prediction of drug release for core/shell coated
stents prepared in the same way as this study, it did not
allow one to predict how changes to the core/shell surface
preparation would influence the release. For example, if as
a result of variations in the surface preparation methods
we obtain different particle sizes, then we are not able to
use this model to predict the effect on the release profile,
since our mathematical solution is in terms of bulk
(or ‘effective’) parameters. Nevertheless, we anticipate that
Fig. 8 The degree of endothelial coverage after stent
implantation for 1, 3, and 6 months by SEM. The surfaces of all
stent groups werepartially covered with cobblestone-like endothelial
cells at 1 month. After 3 and 6 months, the DPS-Hs had adhered a
small amount of platelet and fibrin, and the morphology of the
adhered cells seemed to become oval after their initial roundness.
The BPSs and SESs seemed to have clearer stent shapes
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this model will still be very useful in these cases. For
example, if the parameters of the coating preparation
process are modified, then we may obtain experimental
data at a smaller number of time points and extrapolate
them to later time points. Furthermore, a validated model
of drug release in vitro may be extrapolated to in vivo by
coupling the drug release model to a model of drug
uptake in arterial tissue (see for example62).
In the early period after stent implantation, platelets are
activated and tend to adhere to the injured intima. A large
release of SZ-21 within the first 12 h was achieved for the
inhibition of platelets to avoid thrombosis. Simulta-
neously, as the endothelial cells begin to adhere to the
surface of the DPS, the modest release of DTX did not
influence the adhesion. Along with the increased release
of DTX during the following period, the proliferation and
migration of HUASMCs were inhibited from adhering to
the intima to avoid excessive endometrial hyperplasia.
The differential release of the two drugs was consistent
with the results in vivo. As approximately 62% of
Fig. 9 Histomorphometric analysis results of BMS, BPS, SES, and DPS after stent implantation for 1 and 3 months. a DPS-Hs inhibited intimal
hyperplasia; the orange triangle turned to inflammatory cells around the stent strut. b The neointimal area of DPS was significantly less than those of
the other groups. c The stenosis rate of DPS was significantly less than those in the other groups. This indicated that the DPS-H inhibited neointimal
hyperplasia and restenosis (S stent, N neointima, L lumen, M media) (*, significant difference p < 0.05)
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SZ-21was released in vitro over 28 days, the least number
of adherent platelets and fibrinogen on DPS was observed
in 1 month accordingly, we could infer a similar drug
release trend in vivo.
The ideal drug release mode should conform to the
healing progress of the damaged endothelium, avoiding
the risk of stent restenosis and late thrombosis caused
by prolonged vascular inflammation and the VSMC
migration into the intima. Good drug loading and
delivery methods are beneficial to accelerate endothelial
repair. The combined use of antithrombotic and anti-
proliferative drugs on stents achieved better repair after
implantation. In our in vivo study, using a porcine model
for the better simulation of coronary stent implantation,
these demands of DPSs were evaluated. The angiography
showed no obvious in-stent thrombosis in the DPS group
during the entire observation stage(1, 3, and 6 months)
compared with the BMSs and traditional DESs in other
studies63. When seen from the surface of the neointima
in the DPC group (1, 3, 6 months), there was less adhesion
of platelet and fibrinogen. Despite the dual antiplatelet
therapy, our DPS loaded with SZ-21indicated the
better effect of anti-coagulation and thrombolytic therapy
for early and late thrombosis than traditional DESs and
may have similar applications as other anti-thrombotic
coating stents (such as heparin-loaded)64. Furthermore,
the DPS also reduced the risk of stent restenosis. There
was a reduced lumen loss rate in the DPS-H group
compared with the other groups from 1 to 6 months. The
neointimal area of the DPS-Hs of DTX was significantly
reduced compared with those of BMSs and BPSs. The
two doses of DTX allowed for the evaluation of the
relationship between drug doses, drug release and anti-
proliferative effect. The DPS-H group showed fast re-
endothelialization with the cobblestone-like endothelial
cell layer during the first month, while the BMS and BPS
groups showed incomplete re-endothelialization in some
local regions. The high dose of DTX not only showed no
prevention of re-endothelialization but also effectively
inhibited intimal hyperplasia because of the diffusion-
controlled release system. This drug release system for
implant coating may therefore reduce or avoid the side
effects induced by a high dose of anti-proliferative drugs
in conventional coatings65. The dual-functional DPSs
with high drug dose showed better application potential
compared with BMSs and SESs in vivo.
Conclusion
Hydrophobic core/hydrophilic shell SZ-21/DTX dual-
drug-loaded stents exhibiting a uniform coating of nano/
micro particles using coaxial electrospraying were pre-
pared. After balloon dilatation, the coating remained
smooth and uniform. The majority of the drugs were
initially released within the slow-release phase; the fast
phase release rate of SZ-21 was greater than that of DTX,
while the slow release rate was over five-fold greater for
SZ-21. The differences between the fast and slow release
rates for SZ-21 and DTX clearly highlight the biphasic
nature of the release. The DPSs showed good blood
and cell compatibility, promoted re-endothelialization
in vivo and reduced in-stent restenosis in porcine cor-
onary arteries. Coaxial electrospraying is a one-step and
effective technique for stent coating with multiple drugs
and has great potential to create the enhanced implants
of the future.
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